America approves pancreatic cancer drug
The U.S. Food and Drug Administration (FDA) has approved a new drug for pancreatic cancer called "Rasunek," which offers an opportunity for patients with the most aggressive form of the disease to extend their survival. The medication, taken in pill form and containing the molecule DaraXonrasib, has shown in clinical trials to double the survival time, with half of the patients who received the drug living more than 13 months, compared to the duration experienced by the group treated with chemotherapy. This breakthrough marks a significant advancement after decades, as it surpasses chemotherapy in effectiveness and targets a protein responsible for multiple types of cancer, opening hope for the development of treatments for other forms of the disease.
Notice: This Is an AI-Generated Summary
Comments (0)